

Low Copy Number of the Fc- γ Receptor 3B Gene *FCGR3B* Is a Risk Factor for Primary Sjögren's Syndrome

JOHANNES C. NOSSENT, MAUREEN RISCHMUELLER, and SUE LESTER

ABSTRACT. Objective. Immune complexes play an important role in the pathogenesis of primary Sjögren's syndrome (pSS). Crosslinking of the neutrophil-specific Fc- γ receptor 3b (*FCGR3B*) facilitates immune complex clearance, and copy number variation (CNV) of the *FCGR3B* gene is known to reduce the uptake, and potentially clearance, of circulating immune complexes. Our objective was to determine whether *FCGR3B* CNV is a risk factor for pSS.

Methods. This was a cross-sectional study of patients with established pSS (n = 174) and population-matched controls (n = 162). *FCGR3B* CNV was determined by a quantitative real-time polymerase chain reaction assay, using genomic DNA as template and Taqman chemistry. Reactions were performed as a duplex, with RNase P as the reference gene. Clinical and serological data were analyzed for their association with *FCGR3B* copy number (CN).

Results. Low *FCGR3B* CN (< 2 copies) was a risk factor for pSS in this cohort (p = 0.016), and combined results from this and a previous study yielded an overall OR of 2.3 (95% CI 1.3, 3.9, p = 0.003). Among patients with pSS in our cohort, low *FCGR3B* CN was not associated with anti-Ro \pm La autoantibodies, but was associated with lower rheumatoid factor titers (p = 0.001) and serum IgG levels (p = 0.031).

Conclusion. We confirmed that, similarly to other systemic autoimmune diseases, *FCGR3B* CN is a genetic susceptibility factor for pSS. As in rheumatoid arthritis, the mechanism does not appear to be related to seropositivity for characteristic autoantibodies. (First Release Sept 1 2012; J Rheumatol 2012;39:2142-7; doi:10.3899/jrheum.120294)

Key Indexing Terms:

FCGR3B GENE COPY NUMBER SJÖGRENS' SYNDROME NEUTROPHILS

Primary Sjögren's syndrome (pSS) is a common systemic autoimmune inflammatory condition. The predominant feature is failure of exocrine glands, although extraglandular manifestations, involving skin, lung, heart, kidneys, and nervous system, are common^{1,2}. Autoantibodies targeting the ribonuclear proteins, Ro and La, are common in pSS and present in up to 80% of patient sera samples³. Although previously thought to be nonpathogenic "epiphenomena,"

From the Department of Rheumatology, Basil Hetzel Institute, The Queen Elizabeth Hospital, Adelaide, Australia; Department of Rheumatology, Institute of Clinical Medicine, University of Tromsø, Tromsø, Norway; and the Discipline of Medicine, University of Adelaide, Adelaide, Australia.

Supported by grants from the Norwegian Rheumatism Association, the North Norwegian Health Authority, and the Hospital Research Foundation.

J.C. Nossent, MD, PhD, Department of Rheumatology, Basil Hetzel Institute, The Queen Elizabeth Hospital, and Department of Rheumatology, Institute of Clinical Medicine, University of Tromsø; M. Rischmueller, MD, Department of Rheumatology, Basil Hetzel Institute, The Queen Elizabeth Hospital, and Discipline of Medicine, University of Adelaide; S. Lester, BSc (Hons), Department of Rheumatology, Basil Hetzel Institute, The Queen Elizabeth Hospital.

Address correspondence to S. Lester, Department of Rheumatology, The Queen Elizabeth Hospital, 28 Woodville Road, Woodville South, 5022 South Australia, Australia. E-mail: susan.lester@health.sa.gov.au
Accepted for publication July 6, 2012.

anti-Ro \pm La are associated with systemic complications such as vasculitis, skin lesions, and neonatal heart block^{4,5}. These autoantibodies are now thought to play a central role in the inflammatory response through immune complexes (IC) that are involved in cytokine release and complement activation^{6,7}.

There is clearly a genetic component to susceptibility for pSS, or specifically, autoantibody-positive pSS^{8,9,10}. Copy number variation (CNV) of the *FCGR3B* gene is a candidate gene of particular interest. CNV is a departure from the normal diploid number of genes (n = 2) that may arise from gene duplication and deletion events, and may contribute substantially to quantitative variation in gene expression. An increasing number of CNV have been characterized in the human genome, with implications for both evolution and disease susceptibility¹¹. CNV has been identified in multiple genes within the Fc- γ receptor (FCGR) gene cluster on chromosome 1q23¹². This cluster carries 5 highly homologous genes that encode for low affinity receptors for IgG-complexed antigens, which are expressed widely throughout the hematopoietic system. These low affinity FCGR are involved in the regulation of a multitude of innate and adaptive immune responses, with implications for both response to infection and susceptibility to autoimmunity¹³.

FCGR3B is an activating glycoprotein found only on the surface of human neutrophils that preferentially binds IgG¹⁴. Cross-linking between FCGR3B and IC initiates an effector response resulting in the clearance of IC^{15,16}. CNV of *FCGR3B* has been well characterized, and there is a clear correlation between gene copy number and FCGR3B cell-surface expression, neutrophil adherence to IgG-coated surfaces, and uptake of IC¹⁷. Multiple studies have confirmed that low (< 2) *FCGR3B* copy number (CN) is a genetic susceptibility factor for systemic autoimmune diseases such as systemic lupus erythematosus (SLE)^{18,19,20} and rheumatoid arthritis (RA)^{21,22}. Only 1 study has examined *FCGR3B* CN in pSS, reporting that, similar to their SLE cohort, both low (< 2) and high (> 2) *FCGR3B* CN was associated with pSS¹⁹.

We examined the association between *FCGR3B* CN and pSS in another cohort of patients.

MATERIALS AND METHODS

Study participants. The study population consisted of 174 white patients with pSS (90% females, median age 58 yrs, 84% seropositive for anti-Ro ± La autoantibodies), who met the revised 2002 American-European consensus research classification criteria for pSS²³, and 162 white population-based controls (53% females, median age 56 yrs). Anti-Ro ± La autoantibody specificity and serum B cell activating factor (BAFF) levels were evaluated as described^{8,9,24}, and patients were also assessed by case note review.

The study was conducted in accord with the Declaration of Helsinki and approved by the Central North Adelaide Health Service Ethics of Human Research Committee. All participants provided informed, written consent.

***FCGR3B* CNV determination.** Genomic DNA was prepared by the salt precipitation method from fresh blood samples, as described¹⁰, and genomic *FCGR3B* CN was determined using a quantitative real-time polymerase chain reaction (qPCR) method²¹. Briefly, a duplex Taqman[®] CN assay was performed, using *FCGR3B*-specific primers (Applied Biosystems, Hs04211858, FAM-MGB dual labeled probe) and RNase P (Applied Biosystems, product 4403326, VIC-TAMRA dual labeled probe) as the reference assay. The assay was performed according to the manufacturer's instructions and PCR were run on an Applied Biosystems 7300 Real Time PCR machine. All samples were tested in triplicate, and fluorescence signals were normalized to ROX dye. CN was determined using Copy Caller software (v.1.0, Applied Biosystems), and results were accepted only when calling confidence for discrete CN assignment was > 80%, and the ΔCq SD between replicates was < 0.20; otherwise, samples were retested.

The Taqman qPCR *FCGR3B* CN assay was initially validated against an endpoint PCR paralog ratio assay, measuring *FCGR2C/FCGR2A* CN ratios²⁰, for which the signal intensity (peak height) for both amplicons (274 and 279 bp) was quantified through a multiplexed fluorescence capillary electrophoresis detection system (Qiaxcel). The rationale for this validation is that several studies have reported complete agreement (i.e., linkage disequilibrium) between *FCGR2C* and *FCGR3B* CN^{12,20}. Three reference samples (1,2,3 CN) validated by this assay were included on each qPCR assay plate to control for possible batch effects.

Statistical analysis. The association between *FCGR3B* CN and disease susceptibility, and other dichotomous variables, was analyzed by chi-square and logistic regression analysis, with results reported as OR. Testing for ordinal relationships between *FCGR3B* CN and other variables was performed using the nonparametric gamma correlation coefficient, and proportional OR as appropriate. All analyses were performed using Statistica v6 (Statsoft).

A random effects metaanalysis of this study and a previous publication,

examining the relationship between low CN of *FCGR3B* and pSS, was performed using the R metafor library^{25,26} and the restricted maximum likelihood method.

P values < 0.05 were considered to indicate statistical significance.

RESULTS

The number of genomic *FCGR3B* copies observed in our study varied from 0 to 4; however, 1–3 copies were the most common. One pSS patient carried no *FCGR3B* (null), and 1 patient and 1 control each carried 4 *FCGR3B* copies. Accordingly, the data were grouped for analysis into < 2, 2, and > 2 copies, respectively.

The distribution of *FCGR3B* CN variants was significantly different between pSS patients and controls (chi-square = 6.10, df = 2, p = 0.047; Table 1). Expressed as OR relative to the normal diploid 2 CN, low (< 2) CN was significantly increased in pSS (OR 2.6, 95% CI 1.2, 5.6, p = 0.016), whereas there was no difference in the frequencies of high (> 2) CN between pSS patients and controls (OR 1.1, 95% CI 0.5, 2.4, p = 0.80). Although the sample sizes in this study were comparatively small, a retrospective power analysis indicated that there was sufficient power (79.6% 1-sided test, 69.5% 2-sided test) to detect a difference in low *FCGR3B* CN frequency between patients and controls.

One previous study evaluated *FCGR3B* CN in pSS¹⁹. In a metaanalytic approach, the combined results from both studies (Figure 1) yielded OR of 2.3 (95% CI 1.3, 3.9, p = 0.003) for low (< 2) CN, and 1.6 (95% CI 0.8, 3.1, p = 0.20) for high (> 2) CN, both expressed relative to the normal diploid 2 CN. Therefore, the association between low *FCGR3B* CN is confirmed in 2 separate studies, but the additional putative association with high *FCGR3B* CN¹⁹ remains unconfirmed. Our observation that high (> 2) *FCGR3B* CN was more frequent in patients with seronegative pSS (Table 1) may be relevant in this context, although the number of seronegative patients was very small.

Given that FCGR play an important role in the clearance of IC, it is relevant to consider whether low *FCGR3B* CN, as a risk factor for pSS, is specifically associated with seropositivity for Ro ± La autoantibodies within patients with pSS. The distribution of *FCGR3B* CN in Ro ± La-seronegative versus seropositive patients with pSS is also shown in Table 1. Although the number of patients with seronegative pSS in this study was limited, the frequency distribution was different between the 2 groups (p = 0.042), which was primarily attributable to a higher proportion of high (> 2) CN in patients with seronegative pSS. The relevance of this observation is uncertain, given the low numbers of patients with seronegative pSS. There was, however, no suggestion that low *FCGR3B* CN is preferentially associated with Ro ± La-seropositive pSS.

In terms of other clinical/serological features, low *FCGR3B* CN was associated with lower rheumatoid factor (RF) titers and lower serum IgG levels (Table 2, Figure 2). There was also a trend for an inverse ordinal relationship

Table 1. Low *FCGR3B* genomic copy numbers (< 2 CN) is associated with primary Sjögren's syndrome (pSS), but not specifically Ro + La autoantibody (seropositive) pSS. The distribution of *FCGR3B* CN was significantly different between pSS patients and controls (p = 0.047). When expressed as OR relative to the normal diploid 2 CN, low (< 2) CN was significantly increased in pSS (p = 0.016), whereas there was no difference in the frequencies of high (> 2) CN between pSS patients and controls (p = 0.80). The frequency distribution was also different when comparing seropositive versus seronegative pSS patients (p = 0.042), which was primarily attributable to a higher proportion of high (> 2) CN in seronegative patients with pSS. There was, however, no suggestion that low (< 2) CN is preferentially associated with Ro + La seropositive pSS.

<i>FCGR3B</i> CN	pSS (n = 174) vs Controls (n = 162)				Seropositive pSS (n = 146) vs Seronegative pSS (n = 27)			
	pSS (%)	Controls (%)	OR (95% CI)	p	Seropositive pSS (%)	Seronegative pSS (%)	OR (95% CI)	p
< 2	25 (14.4)	10 (6.2)	2.6 (1.2, 5.6)	0.016	18 (12.3)	6 (22.2)	0.4 (0.1, 1.2)	0.09
2	135 (77.6)	139 (85.8)	1		119 (81.5)	16 (59.3)	1	
> 2	14 (8.0)	13 (8.0)	1.1 (0.5, 2.4)	0.8	9 (6.2)	5 (18.5)	0.2 (0.1, 0.8)	0.022
Global test	Chi-square = 6.10, df = 2, p = 0.047				Chi-square = 6.34, df = 2, p = 0.042			




Figure 1. Random effects (RE) metaanalysis of the association between *FCGR3B* copy number variations and primary Sjögren's syndrome. The 2 studies available were Mamtani 2010¹⁹ and the current study. (A) < 2 versus 2 *FCGR3B* copies; p = 0.003. (B) > 2 versus 2 *FCGR3B* copies; p = 0.20. RE model indicates the OR (95% CI), estimated by restricted maximum likelihood, for the 2 studies combined.

between *FCGR3B* CN and the proportion of patients with a history of persistent, presumed autoimmune neutropenia, although the number of such patients was low (26/254 = 17%) and this analysis did not achieve statistical significance (p = 0.12; Table 2, Figure 2). There was no observed relationship with age of onset, sex, Schirmer's test results, sialometry results, or C4 or serum BAFF levels (data not shown).

DISCUSSION

We have confirmed that low *FCGR3B* CN is a genetic susceptibility factor for pSS. Our results for the association with low *FCGR3B* CN were very similar to the single previous study of patients with pSS¹⁹, and collectively, the OR for the association with pSS (relative to the normal diploid 2 CN) was estimated as 2.6 (95% CI 1.2, 5.6, p = 0.003). Therefore low *FCGR3B* CN may be a common genetic risk

Table 2. Within patients with primary Sjögren's syndrome there is a positive ordinal relationship between *FCGR3B* copy number and rheumatoid factor (RF) titer and serum IgG levels, and an inverse ordinal trend with the risk of neutropenia.

Variable	N	Ordinal Test	Coefficient	p
RF titer	140	Gamma correlation	0.33	0.001
Serum IgG	138	Gamma correlation	0.20	0.031
Neutropenia (proportion)	26/154 (17%)	Proportional OR	0.46 (0.18, 1.21)	0.12




Figure 2. Box plots of *FCGR3B* copy number (CN) by (A) rheumatoid factor titer (n = 140) and (B) serum IgG (n = 138). The width of the box plots reflects the number of observations. It is evident that the ordinal trends reported in Table 3 are primarily due to low (< 2) *FCGR3B* CN, which is associated with lower RF titers and lower serum IgG. (C) The prevalence of low *FCGR3B* CN is slightly higher in patients with a history of neutropenia, and the prevalence of high *FCGR3B* CN slightly lower, indicative of an inverse ordinal trend.

factor for systemic autoimmune diseases such as SLE^{18,19,20}, RA^{21,22}, and pSS. However, it is also clear that a relatively low proportion (< 20%) of patients with systemic autoimmune diseases appear to carry this genetic risk factor. This may be indicative of underlying disease heterogeneity, in which low *FCGR3B* CN is a risk factor in an as-yet unidentified subgroup of patients.

The exposure of autoantigens in pSS is thought to occur during apoptosis of salivary gland acinar and ductal epithelial cells, which is accompanied by translocation of autoantigens to apoptotic blebs. This local event may initiate an autoimmune reaction that becomes systemic through upregulation of type I interferon signature and abnormal expression of BAFF⁷, and lymphocytic invasion and/or IC-mediated inflammation in other organ systems may result. Circulating IC can be demonstrated in a majority of patients with pSS, and anti-Ro-containing IC are related to continuing systemic immune activation^{27,28,29}. As FCGR form an important pathway for IC clearance^{15,16,17}, it was therefore surprising that we were unable to demonstrate a relation between low *FCGR3B* CN and anti Ro \pm La autoantibodies in pSS. In fact we observed that low *FCGR3B* CN was associated with lower RF titers and serum IgG levels in patients with pSS. We previously demonstrated that diversification of the Ro \pm La autoantibody response in patients with pSS is under genetic control, and correlates strongly with RF titers and serum IgG levels^{5,10}. While our findings in relation to low *FCGR3B* CN are only exploratory, and require replication in future studies, collectively, these results suggest that the autoimmune response may be somewhat attenuated in patients who carried this risk factor. In keeping with our findings, no study to date has been able to demonstrate a relationship between low *FCGR3B* CN and disease-specific autoantibodies in systemic autoimmunity. Therefore, the evidence to date suggests that the pathogenetic mechanisms underpinning the relationship between low *FCGR3B* CN and systemic autoimmunity do not specifically relate to clearance of autoantigen-containing IC. One possibility is that, as FCGR3B is an important defense mechanism for the clearance of microorganisms, low *FCGR3B* CN may delay the resolution of infections, such as Epstein-Barr virus (EBV), which may act as a trigger for systemic autoimmunity in some patients³⁰. In this context, it is perhaps relevant that the single *FCGR3B*-null, seronegative patient with pSS in this study had a history of recurrent EBV infections, and our observation that low *FCGR3B* CN is associated with lower IgG levels is also consistent with this hypothesis.

Other pathogenetic mechanisms may also be relevant, but unfortunately the role of neutrophils and FCGR3B in pSS has not been studied extensively. The expression of FCGR3B is upregulated in the saliva of patients with pSS, suggestive of neutrophil activation in salivary glands³¹. Neutropenia may be a relevant hematological finding in pSS³², and our data were suggestive, but not conclusive, that

low *FCGR3B* CN may be a risk factor for neutropenia in patients with pSS. Clinically relevant autoantibodies targeting the human neutrophil FCGR have been described in pSS^{33,34}, and soluble FCGR3B may act as a ligand for complement receptor activation³⁵. However, factors that influence the relative expression of sFCGR3B versus membrane-bound FCGR3B, in both health and disease, are not understood.

It is also not clear whether the association with systemic autoimmunity can be specifically, or solely, attributable to *FCGR3B* CN. The FCGR gene cluster is a complex genomic region, carrying multiple genes, and is characterized by both single-nucleotide polymorphism (SNP) and CNV polymorphism and linkage disequilibrium. For example, *FCGR3B* and *FCGR2C* CNV appear to be in complete linkage disequilibrium^{12,20}, and *FCGR2C*, although a pseudogene in some individuals, may be expressed in a wider range of cell types, including dendritic and natural killer (NK) cells¹². Recent evidence also suggests that the *FCGR2C-FCGR3B* insertion/deletion extends into *FCGR2B*, the only inhibitory FCGR, and probably deletes a negative regulatory element in the *FCGR2B* promoter in NK cells³⁶. Studies have also implicated SNP in multiple FCGR genes with susceptibility to systemic autoimmunity¹⁶, and 1 study has demonstrated that both *FCGR3B* CNV and SNP polymorphism contribute to SLE susceptibility³⁷. The future challenge will be to integrate CNV and SNP data into FCGR gene-cluster haplotypes to systematically evaluate and contrast disease associations.

Our results confirm that, similar to other systemic autoimmune diseases, low *FCGR3B* CN is a genetic risk factor for pSS. However, the underlying pathogenetic mechanism does not appear to relate specifically to clearance of immune complexes formed by anti-Ro \pm La autoantibodies. Further studies on immune complex clearance in systemic autoimmunity, with specific respect to the role of neutrophils, are warranted, in addition to careful clinical characterization of patients who carry this genetic risk.

ACKNOWLEDGMENT

The authors thank Angela Berry for technical assistance.

REFERENCES

1. Mavragani CP, Moutsopoulos HM. The geoepidemiology of Sjogren's syndrome. *Autoimmun Rev* 2010;9:A305-10.
2. Ramos-Casals M, Tzioufas AG, Font J. Primary Sjogren's syndrome: new clinical and therapeutic concepts. *Ann Rheum Dis* 2005;64:347-54.
3. Hernandez-Molina G, Leal-Alegre G, Michel-Peregrina M. The meaning of anti-Ro and anti-La antibodies in primary Sjogren's syndrome. *Autoimmun Rev* 2010;10:123-5.
4. ter Borg EJ, Risselada AP, Kelder JC. Relation of systemic autoantibodies to the number of extraglandular manifestations in primary Sjogren's Syndrome: A retrospective analysis of 65 patients in the Netherlands. *Semin Arthritis Rheum* 2010; 40:547-51.

5. Beer RG, Rischmueller M, Coates T, Purcell AW, Keech CL, McCluskey J, et al. Nonprecipitating anti-La(SS-B) autoantibodies in primary Sjogren's syndrome. *Clin Immunol Immunopathol* 1996;79:314-8.
6. Lauterbach M, O'Donnell P, Asano K, Mayadas TN. Role of TNF priming and adhesion molecules in neutrophil recruitment to intravascular immune complexes. *J Leukoc Biol* 2008;83:1423-30.
7. Nordmark G, Alm GV, Ronnblom L. Mechanisms of disease: Primary Sjogren's syndrome and the type I interferon system. *Nat Clin Pract Rheumatol* 2006;2:262-9.
8. Downie-Doyle S, Bayat N, Rischmueller M, Lester S. Influence of CTLA4 haplotypes on susceptibility and some extraglandular manifestations in primary Sjogren's syndrome. *Arthritis Rheum* 2006;54:2434-40.
9. Nossent JC, Lester S, Zahra D, Mackay CR, Rischmueller M. Polymorphism in the 5' regulatory region of the B-lymphocyte activating factor gene is associated with the Ro/La autoantibody response and serum BAFF levels in primary Sjogren's syndrome. *Rheumatology* 2008;47:1311-6.
10. Rischmueller M, Lester S, Chen Z, Champion G, Van Den Berg R, Beer R, et al. HLA class II phenotype controls diversification of the autoantibody response in primary Sjogren's syndrome (pSS). *Clin Exp Immunol* 1998;111:365-71.
11. Stankiewicz P, Lupski JR. Structural variation in the human genome and its role in disease. *Annu Rev Med* 2010;61:437-55.
12. Breunis WB, van Mirre E, Geissler J, Laddach N, Wolbink G, van der Schoot E, et al. Copy number variation at the FCGR locus includes FCGR3A, FCGR2C and FCGR3B but not FCGR2A and FCGR2B. *Hum Mutat* 2009;30:E640-50.
13. Nimmerjahn F, Ravetch JV. Fc-gamma receptors as regulators of immune responses. *Nat Rev Immunol* 2008;8:34-47.
14. Mayadas TN, Tsokos GC, Tsuboi N. Mechanisms of immune complex-mediated neutrophil recruitment and tissue injury. *Circulation* 2009;120:2012-24.
15. Li X, Ptakec TS, Brown EE, Edberg JC. Fc-gamma receptors: Structure, function and role as genetic risk factors in SLE. *Genes Immun* 2009;10:380-9.
16. Niederer HA, Clatworthy MR, Willcocks LC, Smith KG. Fc-gamma-RIIB, Fc-gamma-RIIIB, and systemic lupus erythematosus. *Ann NY Acad Sci* 2010;1183:69-88.
17. Willcocks LC, Lyons PA, Clatworthy MR, Robinson JI, Yang W, Newland SA, et al. Copy number of FCGR3B, which is associated with systemic lupus erythematosus, correlates with protein expression and immune complex uptake. *J Exp Med* 2008;205:1573-82.
18. Fanciulli M, Norsworthy PJ, Petretto E, Dong R, Harper L, Kamesh L, et al. FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. *Nat Genet* 2007;39:721-3.
19. Mamtani M, Anaya JM, He W, Ahuja SK. Association of copy number variation in the FCGR3B gene with risk of autoimmune diseases. *Genes Immun* 2010;11:155-60.
20. Niederer HA, Willcocks LC, Rayner TF, Yang W, Lau YL, Williams TN, et al. Copy number, linkage disequilibrium and disease association in the FCGR locus. *Hum Mol Genet* 2010;19:3282-94.
21. Graf SW, Lester S, Nossent H, Hill CL, Proudman S, Lee A, et al. Low copy number of the FCGR3B gene and rheumatoid arthritis: A case control study and meta-analysis. *Arthritis Res Ther* 2012;14:R28.
22. Robinson JI, Carr IM, Cooper DL, Rashid LH, Martin SG, Emery P, et al. Confirmation of association of FCGR3B but not FCGR3A copy number with susceptibility to autoantibody positive rheumatoid arthritis. *Hum Mutat* 2012;33:741-9.
23. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjogren's syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. *Ann Rheum Dis* 2002;61:554-8.
24. Walker J, Gordon T, Lester S, Downie-Doyle S, McEvoy D, Pile K, et al. Increased severity of lower urinary tract symptoms and daytime somnolence in primary Sjogren's syndrome. *J Rheumatol* 2003;30:2406-12.
25. R Development Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2011. [Internet. Accessed July 27, 2012.] Available from: <http://www.R-project.org>
26. Viechtbauer W. Conducting meta-analyses in R with the metafor package. *J Statist Software* 2010;36:1-48.
27. Lawley TJ, Moutsopoulos HM, Katz SI, Theofilopoulos AN, Chused TM, Frank MM. Demonstration of circulating immune complexes in Sjogren's syndrome. *J Immunol* 1979;123:1382-7.
28. Mathsson L, Ahlin E, Sjowall C, Skogh T, Ronnelid J. Cytokine induction by circulating immune complexes and signs of in-vivo complement activation in systemic lupus erythematosus are associated with the occurrence of anti-Sjogren's syndrome A antibodies. *Clin Exp Immunol* 2007;147:513-20.
29. Routsias JG, Tzioufas AG. Autoimmune response and target autoantigens in Sjogren's syndrome. *Eur J Clin Invest* 2010;40:1026-36.
30. Pender MP. CD8+ t-cell deficiency, Epstein-Barr virus infection, vitamin D deficiency, and steps to autoimmunity: A unifying hypothesis. *Autoimmune Dis* 2012;2012:189096.
31. Hu S, Gao K, Pollard R, Arellano-Garcia M, Zhou H, Zhang L, et al. Preclinical validation of salivary biomarkers for primary Sjogren's syndrome. *Arthritis Care Res* 2010;62:1633-8.
32. Brito-Zeron P, Soria N, Munoz S, Bove A, Akasbi M, Belenguier R, et al. Prevalence and clinical relevance of autoimmune neutropenia in patients with primary Sjogren's syndrome. *Semin Arthritis Rheum* 2009;38:389-95.
33. Lamour A, Le Corre R, Pennec YL, Youinou P. The presence of anti-Fc gamma receptor autoantibodies is related to the clinical presentation of primary Sjogren's syndrome. *J Rheumatol* 1995;22:2241-5.
34. Lamour A, Le Corre R, Soubrane C, Khayat D, Youinou P. Anti-Fc gamma receptor autoantibodies from patients with Sjogren's syndrome do not react with native receptor on human polymorphonuclear leukocytes. *J Autoimmun* 1996;9:181-91.
35. Galon J, Gauchat JF, Mazieres N, Spagnoli R, Storkus W, Lotze M, et al. Soluble Fc-gamma receptor type III (Fc-gamma-RIII, CD16) triggers cell activation through interaction with complement receptors. *J Immunol* 1996;157:1184-92.
36. van der Heijden J, Breunis WB, Geissler J, de Boer M, van den Berg TK, Kuijpers TW. Phenotypic variation in IgG receptors by nonclassical FCGR2C alleles. *J Immunol* 2012;188:1318-24.
37. Morris DL, Roberts AL, Witherden AS, Tarzi R, Barros P, Whittaker JC, et al. Evidence for both copy number and allelic (NA1/NA2) risk at the FCGR3B locus in systemic lupus erythematosus. *Eur J Hum Genet* 2010;18:1027-31.